The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia

References

• Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995 Oct 19;333(16):1052–1057. PubMed PMID: 7675049.
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017 Sep;92(9):946–965. PubMed PMID: 28782884. .
   PubMed Web of Science ®Google Scholar
• Parikh SA, Strati P, Tsang M, et al. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood. 2016 Apr 7;127(14):1752–1760. PubMed PMID: 26841802.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999 Sep 15;94(6):1848–1854. PubMed PMID: 10477713.
   PubMed Web of Science ®Google Scholar
• Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med. 2008 Dec;264(6):549–562. PubMed PMID: 19017179. .
   PubMed Web of Science ®Google Scholar
• Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015 Oct 22;526(7574):525–530. PubMed PMID: 26466571; PubMed Central PMCID: PMCPMC4815041.
   PubMed Web of Science ®Google Scholar
• Kiefer Y, Schulte C, Tiemann M, et al. Chronic lymphocytic leukemia-associated chromosomal abnormalities and miRNA deregulation. Appl Clin Genet. 2012;5:21–28. PubMed PMID: 23776377; PubMed Central PMCID: PMCPMC3681189.
   PubMedGoogle Scholar
• Burger JA, Ghia P, Rosenwald A, et al. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009 Oct 15;114(16):3367–3375. PubMed PMID: 19636060; PubMed Central PMCID: PMCPMC4969052.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer. 2005 Jan 15;103(2):216–228. PubMed PMID: 15578683. .
   PubMed Web of Science ®Google Scholar
• Grillo-Lopez AJ, White CA, Dallaire BK, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000 Jul;1(1):1–9. PubMed PMID: 11467356.
   PubMedGoogle Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2;376(9747):1164–1174. PubMed PMID: 20888994.
   PubMed Web of Science ®Google Scholar
• Egle A, Steurer M, Melchardt T, et al. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. Ann Hematol. 2018 Jun 4;97(9):1745–1745. PubMed PMID: 29862437.
   Web of Science ®Google Scholar
• Mauro FR, Carella AM, Molica S, et al. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. Leuk Lymphoma. 2017 Jul;58(7):1640–1647. PubMed PMID: 27881039.
   PubMed Web of Science ®Google Scholar
• Chavez JC, Piris-Villaespesa M, Dalia S, et al. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016 Aug;47:78–83. PubMed PMID: 27285853.
   PubMed Web of Science ®Google Scholar
• Jain P, Nogueras Gonzalez GM, Kanagal-Shamanna R, et al. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2018 Jan;180(1):33–40. PubMed PMID: 29164608; PubMed Central PMCID: PMCPMC5745295.
   PubMedGoogle Scholar
• Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15;112(4):975–980. PubMed PMID: 18411418; PubMed Central PMCID: PMCPMC3952498.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928–942. PubMed PMID: 27216274.
   PubMed Web of Science ®Google Scholar
• Cramer P, Langerbeins P, Eichhorst B, et al. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). Eur J Haematol. 2016 Jan;96(1):9–18. PubMed PMID: 26332019.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007 Jul 21;370(9583):230–239. PubMed PMID: 17658394.
   PubMed Web of Science ®Google Scholar
• Kersting S, Neppelenbroek SIM, Visser HPJ, et al. Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):52–57. PubMed PMID: 29097160.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v78–84. PubMed PMID: 26314781.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17;371(3):213–223. PubMed PMID: 24881631; PubMed Central PMCID: PMCPMC4134521.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 4;369(1):32–42. PubMed PMID: 23782158; PubMed Central PMCID: PMCPMC3772525.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016 Jun;17(6):768–778. PubMed PMID: 27178240.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008 Oct 20;26(30):4912–4920. PubMed PMID: 18794548; PubMed Central PMCID: PMCPMC2652085.
   PubMed Web of Science ®Google Scholar
• Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010 Oct 7;116(14):2438–2447. PubMed PMID: 20595516.
   PubMed Web of Science ®Google Scholar
• Van Gelder M, Van Oers MH, Alemayehu WG, et al. Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. Bone Marrow Transplant. 2016 Jun;51(6):799–806. PubMed PMID: 26878656.
   PubMed Web of Science ®Google Scholar
• Kater AP, Wittebol S, Chamuleau ME, et al. Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011. Neth J Med. 2011 Oct;69(10):422–429. PubMed PMID: 22058261.
   PubMed Web of Science ®Google Scholar
• Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;2(6): 676–690. PubMed PMID: 23226614; PubMed Central PMCID: PMCPMC3512181. eng.
   PubMed Web of Science ®Google Scholar
• Diebolder CA, Beurskens FJ, De Jong RN, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014 Mar 14;343(6176):1260–1263. PubMed PMID: 24626930; PubMed Central PMCID: PMCPMC4250092.
   PubMed Web of Science ®Google Scholar
• Lemery SJ, Zhang J, Rothmann MD, et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res. 2010 Sep 1;16(17):4331–4338. PubMed PMID: 20601446.
   PubMed Web of Science ®Google Scholar
• van Meerten T, Rozemuller H, Hol S, et al. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis. Haematologica. 2010 Dec;95(12):2063–2071. PubMed PMID: 20851867; PubMed Central PMCID: PMCPMC2995564.
   PubMed Web of Science ®Google Scholar
• Bruggeman CW, Dekkers G, Bentlage AEH, et al. Enhanced effector functions due to antibody defucosylation depend on the effector cell fcgamma receptor profile. J Immunol. 2017 Jul 1;199(1):204–211. PubMed PMID: 28566370.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Rossi EA, Stein R, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009 Jan 29;113(5):1062–1070. PubMed PMID: 18941114; PubMed Central PMCID: PMCPMC2635072. eng.
   PubMed Web of Science ®Google Scholar
• Kalaycio ME, George Negrea O, Allen SL, et al. Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia. Leuk Lymphoma. 2016;57(4):803–811. PubMed PMID: 26389849.
   PubMed Web of Science ®Google Scholar
• Babiker HM, Glode AE, Cooke LS, et al. Ublituximab for the treatment of CD20 positive B-cell malignancies. Expert Opin Investig Drugs. 2018 Apr;27(4):407–412. PubMed PMID: 29609506.
   PubMed Web of Science ®Google Scholar
• Sawas A, Farber CM, Schreeder MT, et al. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. Br J Haematol. 2017 Apr;177(2):243–253. PubMed PMID: 28220479; PubMed Central PMCID: PMCPMC5412890.
   PubMed Web of Science ®Google Scholar
• Molica S. Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017. BMC Med. 2017 Aug 16;15(1):156. PubMed PMID: 28810856; PubMed Central PMCID: PMCPMC5558721.
   PubMedGoogle Scholar
• Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013 Jan-Feb;5(1):22–33. PubMed PMID: 23211638; PubMed Central PMCID: PMCPMC3564883. eng.
   PubMed Web of Science ®Google Scholar
• Walshe CA, Beers SA, French RR, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem. 2008 Jun 20;283(25):16971–16984. PubMed PMID: 18426802.
   PubMed Web of Science ®Google Scholar
• Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15 Suppl 1:S3. PubMed PMID: 23566754; PubMed Central PMCID: PMCPMC3624669.
   PubMed Web of Science ®Google Scholar
• Oettgen HC, Bayard PJ, Van Ewijk W, et al. Further biochemical studies of the human B-cell differentiation antigens B1 and B2. Hybridoma. 1983;2(1):17–28. PubMed PMID: 6432678.
   PubMedGoogle Scholar
• Tedder TF, Klejman G, Schlossman SF, et al. Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). J Immunol. 1989 Apr 1;142(7):2560–2568. PubMed PMID: 2466899.
   PubMed Web of Science ®Google Scholar
• Prevodnik VK, Lavrencak J, Horvat M, et al. The predictive significance of CD20 expression in B-cell lymphomas. Diagn Pathol. 2011 Apr 12;6:33. PubMed PMID: 21486448; PubMed Central PMCID: PMCPMC3083324.
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005 Oct;31(6):456–473. PubMed PMID: 16054760. .
   PubMed Web of Science ®Google Scholar
• Beum PV, Peek EM, Lindorfer MA, et al. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol. 2011 Sep 15;187(6):3438–3447. PubMed PMID: 21841127.
   PubMed Web of Science ®Google Scholar
• Skopelja-Gardner S, Jones JD, Hamilton BJ, et al. Role for ZAP-70 signaling in the differential effector functions of rituximab and obinutuzumab (GA101) in chronic lymphocytic leukemia B cells. J Immunol. 2017 Aug 15;199(4):1275–1282. PubMed PMID: 28710251.
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010 Jun 24;115(25):5191–5201. PubMed PMID: 20223920; eng.
   PubMed Web of Science ®Google Scholar
• Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004 Mar 1;172(5):3280–3288. PubMed PMID: 14978136.
   PubMed Web of Science ®Google Scholar
• Klepfish A, Gilles L, Ioannis K, et al. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann N Y Acad Sci. 2009 Sep;1173:865–873. PubMed PMID: 19758239.
   PubMed Web of Science ®Google Scholar
• Beurskens FJ, Lindorfer MA, Farooqui M, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol. 2012 Apr 1;188(7):3532–3541. PubMed PMID: 22368276; PubMed Central PMCID: PMCPMC3311731.
   PubMed Web of Science ®Google Scholar
• Capuano C, Romanelli M, Pighi C, et al. Anti-CD20 therapy acts via FcgammaRIIIA to diminish responsiveness of human natural killer cells. Cancer Res. 2015 Oct 1;75(19):4097–4108. PubMed PMID: 26229120.
   PubMed Web of Science ®Google Scholar
• Wang SY, Racila E, Taylor RP, et al. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. 2008 Feb 1;111(3):1456–1463. PubMed PMID: 18024795; PubMed Central PMCID: PMCPMC2214766.
   PubMed Web of Science ®Google Scholar
• Boross P, Lohse S, Nederend M, et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med. 2013 Aug;5(8):1213–1226. PubMed PMID: 23918228; PubMed Central PMCID: PMCPMC3944462.
   PubMed Web of Science ®Google Scholar
• Lohse S, Loew S, Kretschmer A, et al. Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. Br J Haematol. 2017 Apr 27 PubMed PMID: 28449349. DOI:10.1111/bjh.14624.
   PubMed Web of Science ®Google Scholar
• Davids MS, Brown JR. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Dec;53(12):2362–2370. PubMed PMID: 22616724; PubMed Central PMCID: PMCPMC4557770. .
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015 Dec 17;373(25):2425–2437. PubMed PMID: 26639149; PubMed Central PMCID: PMCPMC4722809.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13;370(11):997–1007. PubMed PMID: 24450857; PubMed Central PMCID: PMCPMC4161365.
   PubMed Web of Science ®Google Scholar
• Mato AR, Hill BT, Lamanna N, et al. Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: results from a Multi-Center Study of 683 Patients. Ann Oncol. 2017 Jan 25 PubMed PMID: 28171884. DOI:10.1093/annonc/mdw???
   PubMed Web of Science ®Google Scholar
• Robertson LE, Plunkett W, McConnell K, et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996 Mar;10(3):456–459. PubMed PMID: 8642861.
   PubMed Web of Science ®Google Scholar
• Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med. 2000 Sep;6(9):1029–1035. PubMed PMID: 10973324.
   PubMed Web of Science ®Google Scholar
• Coutre S, Choi M, Furman RR, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018 Jan 5 PubMed PMID: 29305552. DOI:10.1182/blood-2017-06-788133.
   Web of Science ®Google Scholar
• Da Roit F, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 2015 Jan;100(1):77–86. PubMed PMID: 25344523; PubMed Central PMCID: PMCPMC4281316.
   PubMed Web of Science ®Google Scholar
• Palazzo A, Herter S, Grosmaire L, et al. The PI3Kdelta-selective inhibitor idelalisib minimally interferes with immune effector function mediated by Rituximab or Obinutuzumab and significantly augments B cell depletion in vivo. J Immunol. 2018 Apr 1;200(7):2304–2312. PubMed PMID: 29453281; PubMed Central PMCID: PMCPMC5857647.
   PubMed Web of Science ®Google Scholar
• Pavlasova G, Borsky M, Seda V, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016 Sep 22;128(12):1609–1613. PubMed PMID: 27480113; PubMed Central PMCID: PMCPMC5291297.
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H. Obinutuzumab: what is there to learn from clinical trials? Blood. 2017 Aug 3;130(5):581–589. PubMed PMID: 28584136. .
   PubMed Web of Science ®Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep;15(10):1090–1099. PubMed PMID: 25150798; PubMed Central PMCID: PMCPMC4174348.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018 Mar 22;378(12):1107–1120. PubMed PMID: 29562156.
   PubMed Web of Science ®Google Scholar
• Lagrue K, Carisey A, Morgan DJ, et al. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood. 2015 Jul 2;126(1):50–60. PubMed PMID: 26002964; PubMed Central PMCID: PMCPMC4551357.
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008 Jul 15;14(14):4650–4657. PubMed PMID: 18628480.
   PubMed Web of Science ®Google Scholar
• Itchaki G, Brown JR. Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017 May;26(5):633–650. PubMed PMID: 28388253. .
   PubMed Web of Science ®Google Scholar
• Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017 Jun 29;129(26):3419–3427. PubMed PMID: 28424162; PubMed Central PMCID: PMCPMC5492091.
   PubMed Web of Science ®Google Scholar
• Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009 Feb 12;113(7):1581–1588. PubMed PMID: 18974373; PubMed Central PMCID: PMCPMC2644086.
   PubMed Web of Science ®Google Scholar
• Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015 Sep 2;7(303):303ra139. PubMed PMID: 26333935.
   PubMed Web of Science ®Google Scholar
• Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012 Apr 26;119(17):3940–3950. PubMed PMID: 22308288; PubMed Central PMCID: PMCPMC3350361.
   PubMed Web of Science ®Google Scholar
• Ramos CA, Savoldo B, Torrano V, et al. Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains. J Clin Invest. 2016 Jul 1;126(7):2588–2596. PubMed PMID: 27270177; PubMed Central PMCID: PMCPMC4922690.
   PubMed Web of Science ®Google Scholar
• Besbes S, Billard C. First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer. Cell Death Dis. 2015 Jul 9;6:e1810.
   PubMed Web of Science ®Google Scholar